Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD5 | P21918 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | INSR | P06213 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30081995 | 0.98 | CYP3A4 (0.50) | CYP3A4MAPTMTNR1AMTNR1BGAA | |
| SCHEMBL2060189 | 0.90 | MTNR1A (0.46) | CYP3A4MAPTMTNR1AMTNR1BGAA | |
| SCHEMBL10648397 | 0.89 | HTR2C (0.64) | CYP3A4MAPTMTNR1AMTNR1BGAA | |
| SCHEMBL2060925 | 0.84 | MEN1 (0.43) | CYP3A4MAPTMTNR1AMTNR1BGAA | |
| SCHEMBL23364490 | 0.81 | CYP3A4 (0.56) | CYP3A4MAPTGAASMN1; SMN2KMT2A | |
| SCHEMBL9739179 | 0.79 | PARP10 (0.41) | MTNR1AMTNR1BKDM4E | |
| SCHEMBL10645877 | 0.79 | CYP3A4 (0.62) | CYP3A4MAPTGAASMN1; SMN2KMT2A | |
| SCHEMBL5044544 | 0.78 | DRD2 (0.53) | MAPTMTNR1AMTNR1BGAAHTR2A | |
| SCHEMBL227544 | 0.78 | GAA (0.50) | MAPTMTNR1AMTNR1BGAAHTR2A | |
| SCHEMBL30468429 | 0.78 | GAA (0.50) | MAPTMTNR1AMTNR1BGAAHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840469-B2 | Polymorphic forms of ivabradine hydrochloride | CADILA HEALTHCARE LIMITED (IN) | 2017-12-12 | — | — | US | claimed |
| US-20170217898-A1 | POLYMORPHIC FORMS OF IVABRADINE HYDROCHLORIDE | CADILA HEALTHCARE LTD (IN) | 2017-08-03 | — | — | US | claimed |
| EP-2097383-B1 | Process for preparation of ivabradine hydrochloride | CADILA HEALTHCARE LTD (IN) | 2012-02-08 | — | — | EP | claimed |
| EP-2097383-A2 | PROCESS FOR PREPARATION OF IVABRADINE HYDROCHLORIDE | Cadila Healthcare Limited (IN) | 2009-09-09 | — | — | EP | claimed |
| WO-2008065681-A2 | PROCESS FOR PREPARATION OF IVABRADINE HYDROCHLORIDE | CADILA HEALTHCARE LIMITED (IN) | 2008-06-05 | — | — | WO | claimed |
| CN-111187211-A | Preparation method of dimer impurity in ivabradine hydrochloride intermediate | 北京鑫开元医药科技有限公司海南分公司 | 2020-05-22 | — | — | CN | disclosed |
| EP-3558948-A1 | NEW SALT OF IVABRADINE AND USES THEREOF | Biogena (A.P.I) Ltd (CY) | 2019-10-30 | — | — | EP | disclosed |
| WO-2019202611-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | METROCHEM API PVT (IN) | 2019-10-24 | — | — | WO | disclosed |
| WO-2018115181-A1 | NEW SALT OF IVABRADINE AND USES THEREOF | Biogena (A.P.I) Ltd (CY) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018115181-A1 | NEW SALT OF IVABRADINE AND USES THEREOF | Biogena (A.P.I) Ltd (CY) | 2018-06-28 | — | — | WO | disclosed |
| EP-2566850-B1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF IVABRADINE HYDROBROMIDE SALT | RICHTER GEDEON NYRT (HU) | 2018-04-11 | — | — | EP | disclosed |
| US-9840469-B2 | Polymorphic forms of ivabradine hydrochloride | CADILA HEALTHCARE LIMITED (IN) | 2017-12-12 | — | — | US | disclosed |
| EP-0146787-A2 | Indole derivatives, medicaments containing these compounds, and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1985-07-03 | — | — | EP | disclosed |
| US-4490369-A | HYPOTENSIVE, BRRADYCARDIAL | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-12-25 | — | — | US | disclosed |
| EP-0109636-A2 | Benzazepine derivatives, process for their preparation and their use as pharmaceutical compounds | Dr. Karl Thomae GmbH (DE) | 1984-05-30 | — | — | EP | disclosed |
| EP-0080012-A1 | 6-Chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its acid addition salts and its use as an intermediate | SMITHKLINE BECKMAN CORPORATION (US) | 1983-06-01 | — | — | EP | disclosed |
| EP-0007070-B1 | 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS HAVING DOPAMINE RECEPTOR BLOCKING ACTIVITY | SMITHKLINE BECKMAN CORPORATION (US) | 1983-01-19 | — | — | EP | disclosed |
| EP-0065229-A1 | Benzazepines, process for their preparation and their application as pharmaceutical preparations | Dr. Karl Thomae GmbH (DE) | 1982-11-24 | — | — | EP | disclosed |
| US-4265890-A | ANTIPSYCHOTIC, ANTIEMETICS | SMITHKLINE CORPORATION (US) | 1981-05-05 | — | — | US | disclosed |
| EP-0007070-A1 | 2,3,4,5-Tetrahydro-1H-3-Benzazepines, process for their production and pharmaceutical compositions having dopamine receptor blocking activity | SMITHKLINE BECKMAN CORPORATION (US) | 1980-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217898-A1 | POLYMORPHIC FORMS OF IVABRADINE HYDROCHLORIDE | CYP4F3, CYP4F2, SCN5A | CYP3A4 32/4885MAPT 4445/4885MTNR1A 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.